Northwest Biotherapeutics expands management team
This article was originally published in Scrip
Northwest Biotherapeutics has expanded and changed its management team. Linda Powers, who has been chairman of the board since 2007, has been appointed chief executive officer; Dr Anthony Maida, previously CEO of CancerVax, joins the company as chief operating officer; the former CEO of Northwest Biotherapeutics, Dr Alton Boynton is returning to his position as chief scientific officer; and Les Goldman, a former partner at Skadden, has been named senior vice-president of business development.
You may also be interested in...
Almirall has launched its irritable bowel syndrome drug Constella (linaclotide) in six European countries, with several other launches planned for later this year.
Dermira, a dermatology-focused biotech, has raised $35m in a series B financing.
Clovis Oncology has raised its public offering, announced 11 June, from $170m to $240m.